Zacks Investment Research downgraded shares of CYTRX CORP (CYTR) from OUTPERFORM to NEUTRAL on August 23, 2012, with a target price of $4.80.
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CYTRX CORP (CYTR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment